Rezolute, Inc. RZLT
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
8.13
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$74.4M | — | — | $162.1M |
| 2024 | — | -$68.5M | — | — | $121.0M |
| 2023 | — | -$51.8M | — | -$44.6M | $116.2M |
| 2022 | — | -$41.1M | — | — | $149.5M |
| 2021 | — | -$20.9M | — | — | $26.1M |
| 2020 | — | -$20.3M | — | -$24.2M | $7.4M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Evans Daron | CFO | 2026-03-30 | Buy | 10,000 | $2.85 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer | 2026-03-02 | Tax withheld | 11,439 | $2.99 |
| Evans Daron | CFO | 2026-03-02 | Tax withheld | 11,438 | $2.99 |
| Elam Nevan C | CEO | 2026-03-02 | Tax withheld | 27,618 | $2.99 |
| Hogenhuis Wladimir | director | 2025-12-16 | Buy | 5,650 | $1.69 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer | 2025-12-16 | Buy | 28,000 | $1.70 |
| Evans Daron | CFO | 2025-12-15 | Buy | 40,000 | $1.77 |
| Evans Daron | CFO | 2025-12-15 | Buy | 2,500 | $1.78 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 8.13 (safe)
- Working capital / assets 0.907
- Retained earnings / assets -2.301
- EBIT / assets -0.455
- Equity / liabilities 12.133
Source: SEC EDGAR filings · CIK 0001509261 · as of 2025-06-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.